Medical marijuana: a public health perspective


  • Ushang Desai Department of Environmental & Occupational Health, College of Public Health, University of South Florida, Tampa, FL 33612, USA,
  • Paras Patel College of Pharmacy, Nova Southeastern University, Fort Lauderdale-Davie, FL 33314, USA


Medical Marijuana, Physicians, Public Health, Medical Benefits, Health Risks


Over the few years medical marijuana is growing in the United States. Because of the medical marijuana legislators able to legalized recreational marijuana in the two states in the US. Marijuana has several potential benefits that help in certain disease. The delivery of marijuana is also important because smoking marijuana has severe side effects. Physicians also play important role in medical marijuana, physicians also divided on the use of medical marijuana. Their attitude towards medical marijuana important for the treatment of disease is important for the community. Marijuana is the most commonly used illegal drug in the US and all over world, several risks associated with it. Major concern is medical marijuana increased the use of marijuana and will create the public health problem in the society. There are several medical benefits from the marijuana but require more research to establish the marijuana as a medicine. Control of medical marijuana is also major issue for the law enforcement agencies and challenge for policymakers also in the United States.


Grant BF, Pickering R. The relationship between cannabis use and DSM-IV cannabis abuse and dependence: results from the national longitudinal alcohol epidemiologic survey. J Subst Abuse 1998;10:255-64.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association; 2000.

Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the Future National Survey Results on Drug Use, 1975-2009. Volume I: Secondary school students. NIH Publication No 10-7584. National Institute on Drug Abuse; Bethesda, MD: 2010.

Compton W, Thomas Y, Stinson FS, Grant B. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States - results from the National Epidemiologic Survey of Alcohol and Related Conditions. Arch Gen Psychiatry 2007;64:566-76.

Pedersen W, Skardhamar T. Cannabis and crime: findings from a longitudinal study. Addiction 2010;105:109-18.

Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BE. Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry 2008;69:1354-63.

Hall W, Lynskey M. The challenges in developing a rational cannabis policy. Curr Opin Psychiatr 2009;22:258-62.

Haney M. The marijuana withdrawal syndrome: diagnosis and treatment. Curr Psychiatry Rep 2005;7:360-6.

Marijuana and Medicine: Assessing the Science Base. Joy J, Watson S, Benson J, Institute of Medicine, 1999, National Academic Press, ISBN 0-309-51408-8.

Glass M, Dragunow M, Faull RLM. Cannabinoid receptors in the human brain: A detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997;77:299-318.

Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res 1991;547:267-74.

Miller AS, Walker JM. 1996. Electrophysiological effects of a cannabinoid on neural activity in the globus pallidus. Eur J Pharmacol 304:29-35.

Sanudo-Pena MC, Walker JM. 1997. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat. J Neurophysiol 1997;77:1635-8.

Consroe P. Clinical and experimental reports of marijuana and cannabinoids in spastic disorders. In: Nahas GG, Sutin KM, Harvey DJ, Agurell S, Editors, Marijuana and Medicine. Totowa, NJ: Humana Press;1998.

Grinspoon L, Bakalar JB. Marijuana: The Forbidden Medicine. New Haven: Yale University Press; 1993.

Ames FR. Anticonvulsant effect of cannabidiol. S Afr Med J 1986;69:14.

French J. The art of antiepileptic trial design. Adv Neurol 1998;76:113-23.

Volicer L, Smith S, Volicer BJ. Effect of seizures on progression of dementia of the Alzheimer type. Dementia 1995;6:258-63.

Volicer L, Stelly M, Morris J, McLaughlin J, Volicer BJ. 1997. Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease. Int J Geriatr Psychiatry 1997;12:913-9.

Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE: Monitoring the Future National Survey Results Adolescent Drug Use: Overview of Key Findings, 2011. Ann Arbor, Institute for Social Research, The University of Michigan, 2012.

Hall W. The adverse health effects of cannabis use: what are they, and what are their implications for policy? Int J Drug Policy 2009;20:458-66.

Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:849-63.

Anthony L, Warner L, Kessler R. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Study. Clin Exp Psychopharmacol 1994;2:244-68.

Substance Abuse and Mental Health Services Administration: Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings: NSDUH Series 11–14. DHHS Publication (SMA) 11–4658. Rockville, Md, Substance Abuse and Mental Health Services Administration, 2011.

Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004;61:807-16.

Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl) 1999; 141:395-404.

Budney AJ, Moore BA. Development and consequences of cannabis dependence. J Clin Pharmacol 2002;42(11. Suppl):28S-33S.

Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004;161:1967-77.

Haney M. The marijuana withdrawal syndrome: diagnosis and treatment. Curr Psychiatry Rep 2005;7:360-6.

Moore BA, Budney AJ. Relapse in outpatient treatment for marijuana dependence. J Subst Abuse Treat 2003;25:85-9.

Cerda M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse, and dependence. Drug Alcohol Depend 2011;120:22-7.

Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ 2012;344:e536.

Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-28.

D’Sousa DC. Cannabinoids and psychosis. Int Rev Neurobiol 2007;78:849-63.

Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004;184:110-7.

Di Forti M, Morgan C , Dazzan P, Pariante C , Mondelli V, Marques TR, Handley R, Luzi S, Russo M, Paparelli A, Butt A, Stilo SA, Wiffen B, Powell J, Murray RM. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009;195:488-91.

Paparelli A, Di Forti M, Morrison PD, Murray RM. Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci 2011;5:1.

Newell GR, Mansell PW, Wilson MB, Lynch HK, Spitz MR, Hersh EM. Risk factor analysis among men referred for possible acquired immune deficiency syndrome. Prev Med 1985;14:81-91.

Denning DW, Follansbee SE, Scolaro M, et al. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:654-62.

Caiaffa WT, Vlahov D, Graham N, Astemborski J, Solomon L, Nelson KE, Muñoz A. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. Am J Respir Crit Care Med 1994;150:1493-8.

McCrimmon KK, Mitchell N. Colorado schools see potent influence from nearby medical marijuana sites. Education Week, Feb 6, 2012. Available at Accessed 6 November 2012.

Colorado Department of Public Health and Environment. Colorado Medical Marijuana Registry home page. Available at Satellite/CDPHE-CHEIS/CBON/1251593016680. Accessed 6 November 2012.

Nussbaum AM, Boyer JA, Kondrad EC. “But my doctor recommended pot”: medical marijuana and the patient-physician relationship. J Gen Intern Med 2011;26:1364-7.

Kondrad E, Reid A. Colorado Family Physicians’ Attitudes toward Medical Marijuana. J Am Board Fam Med 2013;26:52-60.

Kleber HD, DuPont RL. Physicians and medical marijuana. Am J Psychiatry 2012;169:564-8.




How to Cite

Desai, U., & Patel, P. (2017). Medical marijuana: a public health perspective. International Journal of Basic & Clinical Pharmacology, 2(2), 136–143. Retrieved from



Review Articles